四川港通医疗设备集团股份有限公司 2025年半年度募集资金存放与使用情况的专项报告 根据《上市公司募集资金监管规则》和《深圳证券交易所上市公司自律监管指 引第2号-创业板上市公司规范运作》等有关规定，现将本公司2025年半年度募集资 金存放与使用情况说明如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 经中国证券监督管理委员会证监许可〔2023〕1108号文同意注册，并经深圳证 券交易所同意，本公司由主承销商中信建投证券股份有限公司通过深圳证券交易所 系统于2023年7月11日采用网上发行，网下配售，战略投资者配售方式，向社会公众 公开发行了普通股（A股）股票2,500.00万股，发行价为每股人民币31.16元。截至 2023年7月17日，本公司共募集资金779,000,000.00元，扣除发行费用89,004,023.26 元后，募集资金净额为689,995,976.74元。 上述募集资金净额已经致同会计师事务所（特殊普通合伙）致同验字（2023） 第510C000333号《验资报告》验证。 （二）以前年度已使用金额、本报告期使用金额及当前余额 1、以前年度已使用金额 截至2024年12月 ...

证券代码：301515 证券简称：港通医疗 公告编号：2025-051 四川港通医疗设备集团股份有限公司 关于 2025 年半年度计提资产减值准备的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 四川港通医疗设备集团股份有限公司（以下简称"公司"或"本公司"）于 2025 年 8 月 26 日召开第五届董事会审计委员会第一次会议，于 2025 年 8 月 27 日召开第五届董事会第四次会议，审议通过《关于 2025 年半年度计提资产减值准 备的议案》。现将相关事宜公告如下： 一、本次计提减值准备的情况概述 根据《企业会计准则》《深圳证券交易所创业板股票上市规则》《深圳证券 交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》及公司会计 政策等规定，为客观、公允地反映公司截至 2025 年 6 月 30 日的财务状况及经营 成果，公司本着谨慎性原则，对 2025 年半年度合并财务报表范围内可能发生减值 迹象的资产进行全面清查和减值测试，对存在减值迹象的资产计提相应减值准备。 二、本次计提减值准备的范围和总金额 2025 年 1—6 月，公司计提 ...

四川港通医疗设备集团股份有限公司 2025 年 1-6 月非经营性资金占用及其他关联资金往来情况汇总表 单位：万元 | 非经营性资金占用 | 资金占用方 | 占用方与上市 公司的关联关 | 上市公司核算的 | 年期初占 2025 | 2025 年半年度占 用累计发生金额 | 2025 年半年度占 用资金的利息（如 | 2025 年半年度 偿还累计发生 | 年半年度期 2025 | 占用形 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 名称 | | 会计科目 | 用资金余额 | | | | 末占用资金余额 | 成原因 | | | | | 系 | | | （不含利息） | 有） | 金额 | | | | | 控股股东、实际控制人及 | | | | | | | | | | 非经营性占用 | | 其附属企业 | | | | | | | | | | 非经营性占用 | | 小计 | - | - | - | | | | | | | - | | 前控股股东、实际控制人 | | | | | | | | | | 非 ...

进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 四川港通医疗设备集团股份有限公司（以下简称"公司"或"本公司"） 于 2024 年 4 月 22 日召开第四届董事会第十四次会议及第四届监事会第十 四次会议，并于 2024 年 5 月 15 日召开 2023 年年度股东大会，审议通过了《关 于使用部分闲置募集资金（含超募资金）及自有资金进行现金管理的议案》， 同意公司在确保不影响正常运营和募集资金投资项目建设的情况下，使用 不超过 49,000.00 万元（含本数）暂时闲置募集资金（含超募资金）及不超 过 25,000.00 万元（含本数）自有资金，合计不超过人民币 74,000.00 万元 （含本数）进行现金管理，上述额度自股东大会审议通过之日起 12 个月内 有效，在前述额度和期限范围内资金可循环滚动使用。具体内容详见公司于 2024 年 4 月 24 日、2024 年 5 月 15 日披露于巨潮资讯网（www.cninfo.com.cn） 的相关公告。 本公司于 2025 年 4 月 17 日召开第四届董事会第十九次会议及第四届监 ...

四川港通医疗设备集团股份有限公司 2025 年半年度报告全文 四川港通医疗设备集团股份有限公司 2025 年半年度报告 2025-049 2025 年 8 月 1 四川港通医疗设备集团股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 本报告中如有涉及未来计划等方面的内容，均不构成本公司对任何投资者 及相关人士的承诺，投资者及相关人士均应对此保持足够的风险认识，并且 应当理解计划与承诺之间的差异。 公司存在的风险详细内容见本报告"第三节 管理层讨论与分析"之"十、 公司面临的风险和应对措施"，敬请广大投资者注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | | | | 第二节 | 公司简介和主要财务指标 7 | | | --- | --- | --- | | 第三节 | 管理层讨论与分析 10 | | | 第四节 | 公司治理、环境和社会 29 | | | 第五节 | 重要事项 | 30 | | 第六节 | 股份变动及股东情况 | 34 | | 第七节 | 债券相关情况 | 40 | | 第八节 | 财务报告 | 41 | 公司董事会及董事、高级管理人员保证半年 ...

（编辑 袁冠琳） 证券日报网讯 开勒股份8月28日在互动平台回答投资者提问时表示，公司将严格按照相关法律法规要 求，及时、准确、完整地履行信息披露义务，切实保障投资者的知情权。敬请投资者理性投资，注意投 资风险。 ...

Core Viewpoint - As of August 26, 2025, the stock price of Kangtong Medical (301515) closed at 23.35 yuan, experiencing a decline of 0.34% with a trading volume of 1.93 million hands and a transaction amount of 45.37 million yuan [1] Financial Performance - The company's main revenue for Q1 2025 was 24.29 million yuan, a year-on-year decrease of 68.09% - The net profit attributable to the parent company was 1.58 million yuan, down 85.25% year-on-year - The net profit after deducting non-recurring gains and losses was 1.41 million yuan, a decline of 86.46% year-on-year - The debt ratio stood at 36.26%, with financial expenses recorded at -515,200 yuan and a gross profit margin of 36.15% [3] Market Position - Kangtong Medical's total market value is 2.335 billion yuan, significantly lower than the industry average of 12.328 billion yuan, ranking 118 out of 123 in the medical device industry - The company's net assets are 1.248 billion yuan, compared to the industry average of 3.881 billion yuan, also ranking 98 out of 123 - The price-to-earnings ratio (P/E) is 369.71, much higher than the industry average of 65.92, ranking 93 out of 123 - The price-to-book ratio (P/B) is 1.89, lower than the industry average of 4.03, ranking 31 out of 123 - The gross margin is 36.15%, compared to the industry average of 51.3%, ranking 92 out of 123 - The net margin is 6.5%, lower than the industry average of 11.2%, ranking 78 out of 123 - The return on equity (ROE) is 0.12%, significantly below the industry average of 1.92%, ranking 96 out of 123 [3]

Group 1 - The core viewpoint of the news is that Kangtong Medical has experienced a decline in stock performance and financial metrics, indicating potential challenges ahead [1][2] - On August 22, Kangtong Medical's stock fell by 0.50%, with a trading volume of 60.65 million yuan, and a net financing purchase of 1.76 million yuan [1] - As of August 22, the total margin balance for Kangtong Medical was 58.42 million yuan, accounting for 3.54% of its market capitalization, which is above the 90th percentile of the past year [1] Group 2 - Kangtong Medical's main business involves providing medical institutions with integrated solutions centered on medical gas systems and clean operating rooms, with revenue composition being 65.42% from clean equipment and systems, 29.43% from medical gas equipment, and 3.01% from other medical devices [1] - As of August 20, the number of shareholders for Kangtong Medical was 8,690, a decrease of 8.23%, while the average circulating shares per person increased by 8.96% to 7,327 shares [2] - For the first quarter of 2025, Kangtong Medical reported a revenue of 24.29 million yuan, a year-on-year decrease of 68.09%, and a net profit attributable to the parent company of 1.58 million yuan, down 85.25% year-on-year [2] Group 3 - Since its A-share listing, Kangtong Medical has distributed a total of 48.99 million yuan in dividends [3]

Core Viewpoint - The announcement from Hongtong Medical indicates a strategic shift in its subsidiary's operational scope to align with future business development needs [1] Group 1 - Hongtong Medical's wholly-owned subsidiary, Hongtong General Equipment Manufacturing (Chengdu) Co., Ltd., has undergone a change in its business scope [1] - The company has completed the necessary business registration changes and received a new business license from the Administrative Approval Bureau of Jianyang, Sichuan Province [1]

Group 1 - The stock price of Kangtong Medical (301515) closed at 23.65 yuan on August 22, 2025, down 0.5% with a turnover rate of 4.06% and a trading volume of 25,800 hands, resulting in a transaction amount of 60.65 million yuan [1] - On August 22, the net inflow of main funds was 5.62 million yuan, accounting for 9.26% of the total transaction amount, while retail investors experienced a net outflow of 3.14 million yuan, accounting for 5.18% [1][2] - The company's main business includes the research, design, manufacturing, integration, and operation services of medical gas equipment and systems, as well as medical clean equipment and systems [3] Group 2 - Kangtong Medical's total market value is 2.365 billion yuan, with a net asset of 1.248 billion yuan and a net profit of 1.579 million yuan, ranking 118th, 98th, and 99th respectively in the medical device industry [3] - The company's first-quarter report for 2025 shows a main revenue of 24.29 million yuan, a year-on-year decrease of 68.09%, and a net profit attributable to shareholders of 1.579 million yuan, down 85.25% year-on-year [3] - The company's price-to-earnings ratio (P/E) is 374.46, significantly higher than the industry average of 77.99, indicating potential overvaluation [3]